"But experts and health care advocates said that limitations with the new service could undermine its value to consumers. "The prices are absolutely cheaper than list prices, but only for cash patients or patients whose insurance does not sufficiently cover these drugs," Yunan Ji, a health policy expert at Georgetown's McDonough School of Business, told CBS News. "For a small share of the market, it will deliver meaningful savings, but it is not going to change the whole drug pricing landscape for most Americans.""
"The White House told CBS News that such discounts only exist because the Trump administration negotiated so-called "most-favored-nation" agreements with pharmaceutical firms to lower prices. Under that policy, drugmakers must sell meds to U.S. customers at the same prices available in other countries, including those with lower drug costs. TrumpRx is also focused on offering the lowest prices on branded products, the White House noted, acknowledging that more affordable generic versions of the drugs may be available elsewhere."
TrumpRx launched offering discounted branded prescription drugs and received presidential praise as transformative. Experts and advocates note limitations that constrain consumer benefit. Discounts reduce prices compared with list prices primarily for cash-paying patients or those whose insurance fails to cover drugs adequately. The program will provide meaningful savings for a small share of the market but is unlikely to change the overall drug pricing landscape for most Americans. The service functions largely as a catalog of manufacturer coupon programs and lacks comprehensive price-comparison and one-stop shopping features. The White House credits negotiated most-favored-nation agreements for the discounts and notes generics may still be cheaper.
Read at Cbsnews
Unable to calculate read time
Collection
[
|
...
]